From Indian Patent Office
Bajaj Healthcare has moved the Indian Patent Office requesting to grant a compulsory license for manufacturing & supply of Covid-19 drug Baricitinib (API and Formulation).Currently, Eli Lilly and company has received Emergency Use Authorization (EUA) from U.S. Food and Drug Administration (FDA) for the distribution and emergency use of Baricitinib to be used in combination with remdesivir in hospitalized adult and pediatric patients aged more than two years with suspected or laboratory confirmed COVID-19 requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).
Emergency Use Authorization (EUA) permits the emergency use of baricitinib, in combination with remdesivir, for treatment of suspected or laboratory confirmed COVID-19 in hospitalized adults and paediatric patients above two years of age requiring supplemental oxygen, invasive mechanical ventilation, or ECMO.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
